List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4844000/publications.pdf Version: 2024-02-01



RDIAN ACAN

#	Article	IF	CITATIONS
1	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	12.6	1,054
2	The Influence of <i>CCL3L1</i> Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility. Science, 2005, 307, 1434-1440.	12.6	1,040
3	Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 194-200.	2.1	442
4	Clinical Outcomes of Elite Controllers, Viremic Controllers, and Longâ€Term Nonprogressors in the US Department of Defense HIV Natural History Study. Journal of Infectious Diseases, 2009, 200, 1714-1723.	4.0	268
5	Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. Aids, 2009, 23, 41-50.	2.2	232
6	Incidence and risk factors for the occurrence of nonâ€AIDSâ€defining cancers among human immunodeficiency virusâ€infected individuals. Cancer, 2005, 104, 1505-1511.	4.1	212
7	Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic. PLoS ONE, 2010, 5, e10106.	2.5	202
8	Apolipoprotein (apo) E4 enhances HIV-1 cell entry <i>in vitro</i> , and the <i>APOE</i> ε4/ε4 genotype accelerates HIV disease progression. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8718-8723.	7.1	181
9	Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. Aids, 2010, 24, 535-543.	2.2	172
10	Duffy Antigen Receptor for Chemokines Mediates trans-Infection of HIV-1 from Red Blood Cells to Target Cells and Affects HIV-AIDS Susceptibility. Cell Host and Microbe, 2008, 4, 52-62.	11.0	166
11	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nature Immunology, 2007, 8, 1324-1336.	14.5	152
12	Broad-spectrum respiratory tract pathogen identification using resequencing DNA microarrays. Genome Research, 2006, 16, 527-535.	5.5	130
13	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Nature Medicine, 2008, 14, 413-420.	30.7	118
14	Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters. Journal of Infectious Diseases, 2012, 205, 185-193.	4.0	108
15	Trends and Causes of Hospitalizations Among HIV-Infected Persons During the Late HAART Era: What Is the Impact of CD4 Counts and HAART Use?. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 248-257.	2.1	92
16	Laboratory diagnosis of Bartonella infections. Clinics in Laboratory Medicine, 2002, 22, 937-962.	1.4	77
17	Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology, 2013, 80, 371-379.	1.1	77
18	A Randomized Clinical Trial Comparing Revaccination with Pneumococcal Conjugate Vaccine to Polysaccharide Vaccine among HIVâ€Infected Adults. Journal of Infectious Diseases, 2010, 202, 1114-1125.	4.0	76

#	Article	IF	CITATIONS
19	SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies. Science Translational Medicine, 2022, 14, eabn8543.	12.4	75
20	Prevalence and Factors Associated With Sleep Disturbances Among Early-Treated HIV-Infected Persons. Clinical Infectious Diseases, 2012, 54, 1485-1494.	5.8	74
21	Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: Another benefit of HAART in those with preserved CD4 count. Vaccine, 2009, 27, 4731-4738.	3.8	73
22	Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Research and Therapy, 2010, 7, 14.	1.7	73
23	Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight, 2019, 4, .	5.0	70
24	HIV-1 Disease-Influencing Effects Associated with ZNRD1, HCP5 and HLA-C Alleles Are Attributable Mainly to Either HLA-A10 or HLA-B*57 Alleles. PLoS ONE, 2008, 3, e3636.	2.5	70
25	Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus 1–Infected Individuals. JAMA Internal Medicine, 2015, 175, 88.	5.1	69
26	Hepatitis E Virus Infection in HIV-infected Persons. Emerging Infectious Diseases, 2012, 18, 502-506.	4.3	67
27	Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIVâ€Infected Individuals during the Past 20 Years. Clinical Infectious Diseases, 2010, 50, 426-436.	5.8	66
28	Virologic Response Differences Between African Americans and European Americans Initiating Highly Active Antiretroviral Therapy With Equal Access to Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 574-580.	2.1	65
29	Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure. Clinical Infectious Diseases, 2019, 69, 2145-2152.	5.8	62
30	Long-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected Adults. Journal of Infectious Diseases, 2011, 203, 1815-1823.	4.0	57
31	Obesity among HIV-infected persons: impact of weight on CD4 cell count. Aids, 2010, 24, 1069-1072.	2.2	53
32	Cutaneous Malignancies Among HIV-Infected Persons. Archives of Internal Medicine, 2009, 169, 1130.	3.8	51
33	Increasing Age at HIV Seroconversion From 18 to 40 Years Is Associated With Favorable Virologic and Immunologic Responses to HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 40-47.	2.1	50
34	D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLoS ONE, 2016, 11, e0152588.	2.5	50
35	Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS. PLoS ONE, 2011, 6, e17956.	2.5	48
36	HIV Outcomes in Hepatitis B Virus Coinfected Individuals on HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 197-205.	2.1	47

#	Article	IF	CITATIONS
37	Responsiveness of T Cells to Interleukinâ€7 Is Associated with Higher CD4+T Cell Counts in HIVâ€1–Positive Individuals with Highly Active Antiretroviral Therapy–Induced Viral Load Suppression. Journal of Infectious Diseases, 2009, 199, 1872-1882.	4.0	46
38	Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia. Clinical Infectious Diseases, 2020, 71, 652-660.	5.8	44
39	Effectiveness of highly-active antiretroviral therapy by race/ethnicity. Aids, 2006, 20, 1531-1538.	2.2	43
40	Impact of Weight on Immune Cell Counts among HIV-Infected Persons. Vaccine Journal, 2011, 18, 940-946.	3.1	40
41	A Single Dose of Benzathine Penicillin G Is as Effective as Multiple Doses of Benzathine Penicillin G for the Treatment of HIV-Infected Persons With Early Syphilis. Clinical Infectious Diseases, 2015, 60, 653-660.	5.8	40
42	Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. Aids, 2010, 24, 545-555.	2.2	38
43	CD4 T Cell Count Reconstitution in HIV Controllers after Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 50, 1187-1191.	5.8	36
44	ls HIV Becoming More Virulent? Initial CD4 Cell Counts among HIV Seroconverters during the Course of the HIV Epidemic: 1985–2007. Clinical Infectious Diseases, 2009, 48, 1285-1292.	5.8	33
45	The VACS Index Predicts Mortality in a Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 226-230.	2.1	33
46	Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Research and Therapy, 2011, 8, 2.	1.7	32
47	Independent Effects of Genetic Variations in Mannoseâ€Binding Lectin Influence the Course of HIV Disease: The Advantage of Heterozygosity for Coding Mutations. Journal of Infectious Diseases, 2008, 198, 72-80.	4.0	31
48	Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy. Alcoholism: Clinical and Experimental Research, 2016, 40, 529-535.	2.4	30
49	Unintended Smallpox Vaccination of HIV-1–Infected Individuals in the United States Military. Clinical Infectious Diseases, 2004, 38, 1320-1322.	5.8	29
50	Pulmonary Hemorrhage Syndrome Associated with an Autochthonous Case of Dengue Hemorrhagic Fever. Southern Medical Journal, 2004, 97, 688-691.	0.7	29
51	Results of a 25-Year Longitudinal Analysis of the Serologic Incidence of Syphilis in a Cohort of HIV-Infected Patients With Unrestricted Access to Care. Sexually Transmitted Diseases, 2012, 39, 440-448.	1.7	29
52	The Effect of Human Immunodeficiency Virus on Hepatitis B Virus Serologic Status in Co-Infected Adults. PLoS ONE, 2010, 5, e8687.	2.5	27
53	Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort. PLoS ONE, 2012, 7, e47310.	2.5	27
54	Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic?. Aids, 2010, 24, 2881-2883.	2.2	26

#	Article	IF	CITATIONS
55	Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study. Journal of the International AIDS Society, 2016, 19, 20524.	3.0	25
56	The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity. Clinical Infectious Diseases, 2022, 74, 897-900.	5.8	24
57	CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected Individuals. PLoS ONE, 2008, 3, e3165.	2.5	23
58	Role of CCL3L1-CCR5 Genotypes in the Epidemic Spread of HIV-1 and Evaluation of Vaccine Efficacy. PLoS ONE, 2008, 3, e3671.	2.5	23
59	Elevated CD8 Counts During HAART Are Associated With HIV Virologic Treatment Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 396-403.	2.1	23
60	Risk Factors Influencing Antibody Responses to Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Antigens in Patients Under Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 83-90.	2.1	23
61	Factors associated with HIV viral load "blips―and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case–control study. AIDS Research and Therapy, 2016, 13, 16.	1.7	23
62	Understanding "Hybrid Immunityâ€: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases, 2023, 76, e439-e449.	5.8	23
63	Gonorrhoea or chlamydia in a US military HIV-positive cohort. Sexually Transmitted Infections, 2012, 88, 266-271.	1.9	22
64	MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity. PLoS Pathogens, 2016, 12, e1005580.	4.7	22
65	History of U.S. Military Contributions to the Study of Bacterial Zoonoses. Military Medicine, 2005, 170, 39-48.	0.8	21
66	Early Postseroconversion CD4 Cell Counts Independently Predict CD4 Cell Count Recovery in HIV-1–Postive Subjects Receiving Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 387-395.	2.1	21
67	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. Aids, 2016, 30, 2659-2663.	2.2	21
68	Health-related quality of life among military HIV patients on antiretroviral therapy. PLoS ONE, 2017, 12, e0178953.	2.5	21
69	Immunologic resilience and COVID-19 survival advantage. Journal of Allergy and Clinical Immunology, 2021, 148, 1176-1191.	2.9	21
70	Sensitivity of the Multispot HIV-1/HIV-2 Rapid Test Using Samples from Human Immunodeficiency Virus Type 1-Positive Individuals with Various Levels of Exposure to Highly Active Antiretroviral Therapy. Journal of Clinical Microbiology, 2006, 44, 1831-1833.	3.9	20
71	The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 305-309.	2.1	20
72	Clinical Evaluation of the Potential Utility of Computational Modeling as an HIV Treatment Selection Tool by Physicians with Considerable HIV Experience. AIDS Patient Care and STDs, 2011, 25, 29-36.	2.5	20

#	Article	IF	CITATIONS
73	Association of Methicillin-Resistant Staphylococcus aureus (MRSA) Colonization With High-Risk Sexual Behaviors in Persons Infected With Human Immunodeficiency Virus (HIV). Medicine (United) Tj ETQq1	1 0.7 8.4 314	rg BT B/Overloc
74	The Timing of Hepatitis B Virus (HBV) Immunization Relative to Human Immunodeficiency Virus (HIV) Diagnosis and the Risk of HBV Infection Following HIV Diagnosis. American Journal of Epidemiology, 2011, 173, 84-93.	3.4	17
75	Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia. BMC Research Notes, 2015, 8, 595.	1.4	17
76	The Association between Sexually Transmitted Infections, Length of Service and Other Demographic Factors in the U.S. Military. PLoS ONE, 2016, 11, e0167892.	2.5	17
77	<scp>HIV</scp> viraemia during hepatitis <scp>B</scp> vaccination shortens the duration of protective antibody levels. HIV Medicine, 2015, 16, 161-167.	2.2	16
78	A Comparison of HAART Outcomes between the US Military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS). PLoS ONE, 2013, 8, e62273.	2.5	16
79	Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) Instrument in Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab517.	0.9	16
80	COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment. Open Forum Infectious Diseases, 2021, 8, ofab556.	0.9	16
81	Randomized, Double-Blind, Placebo-Controlled Study on Decolonization Procedures for Methicillin-Resistant Staphylococcus aureus (MRSA) among HIV-Infected Adults. PLoS ONE, 2015, 10, e0128071.	2.5	15
82	Lower health-related quality of life predicts all-cause hospitalization among HIV-infected individuals. Health and Quality of Life Outcomes, 2018, 16, 107.	2.4	15
83	HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function. Current HIV Research, 2014, 12, 50-59.	0.5	14
84	Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 364-369.	2.1	14
85	CD4 rate of increase is preferred to CD4 threshold for predicting outcomes among virologically suppressed HIV-infected adults on antiretroviral therapy. PLoS ONE, 2020, 15, e0227124.	2.5	14
86	Clinical, Immunological, and Virological SARS-CoV-2 Phenotypes in Obese and Nonobese Military Health System Beneficiaries. Journal of Infectious Diseases, 2021, 224, 1462-1472.	4.0	14
87	Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: authors' reply. Aids, 2009, 23, 1791-1792.	2.2	13
88	HIV Infection Among U.S. Army and Air Force Military Personnel: Sociodemographic and Genotyping Analysis. AIDS Research and Human Retroviruses, 2010, 26, 889-894.	1.1	13
89	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. Journal of Antimicrobial Chemotherapy, 2014, 69, 1104-1110.	3.0	13
90	Seroprevalence and Seroincidence of Herpes Simplex Virus (2006–2010), Syphilis (2006–2010), and Vaccine-Preventable Human Papillomavirus Subtypes (2000–2010) Among US Military Personnel. Sexually Transmitted Diseases, 2015, 42, 253-258.	1.7	13

#	Article	IF	CITATIONS
91	Lower Baseline Germinal Center Activity and Preserved Th1 Immunity are Associated with Hepatitis B Vaccine Response in Treated HIV Infection. Pathogens and Immunity, 2017, 2, 66.	3.1	12
92	Hepatitis B Vaccine Antibody Response and the Risk of Clinical AIDS or Death. PLoS ONE, 2012, 7, e33488.	2.5	11
93	Combining Epidemiologic and Biostatistical Tools to Enhance Variable Selection in HIV Cohort Analyses. PLoS ONE, 2014, 9, e87352.	2.5	11
94	Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infectious Diseases, 2016, 16, 351.	2.9	11
95	Medical Encounter Characteristics of HIV Seroconverters in the US Army and Air Force, 2000–2004. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 372-380.	2.1	10
96	Expanded Sexually Transmitted Infection Surveillance Efforts in the United States Military: A Time for Action. Military Medicine, 2013, 178, 1271-1280.	0.8	10
97	Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults. Vaccine, 2016, 34, 5040-5046.	3.8	10
98	The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. Vaccine, 2010, 28, 7583-7588.	3.8	9
99	Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort. AIDS Research and Therapy, 2012, 9, 4.	1.7	9
100	Herpes Zoster Rates Continue to Decline in People Living With Human Immunodeficiency Virus but Remain Higher Than Rates Reported in the General US Population. Clinical Infectious Diseases, 2019, 69, 155-158.	5.8	9
101	Hepatitis B Vaccine Responsiveness and Clinical Outcomes in HIV Controllers. PLoS ONE, 2014, 9, e105591.	2.5	9
102	Potential Use of Microarray Technology for Rapid Identification of Central Nervous System Pathogens. Military Medicine, 2004, 169, 594-599.	0.8	8
103	Specific Behaviors Predict Staphylococcus aureus Colonization and Skin and Soft Tissue Infections Among Human Immunodeficiency Virus-Infected Persons. Open Forum Infectious Diseases, 2015, 2, ofv034.	0.9	8
104	The US Military HIV Natural History Study: Informing Military HIV Care and Policy for Over 30 Years. Military Medicine, 2019, 184, 6-17.	0.8	8
105	Association between depression and HIV treatment outcomes in a US military population with HIV infection. AIDS Research and Therapy, 2021, 18, 29.	1.7	8
106	Are HIV-Positive Persons Progressing Faster After Diagnosis Over the Epidemic?. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, e6-e7.	2.1	7
107	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	3.0	7
108	Predictors of health-related quality of life among military HIV-infected individuals. Quality of Life Research, 2020, 29, 1855-1869.	3.1	7

#	Article	IF	CITATIONS
109	Generalized Confidence Intervals and Fiducial Intervals for Some Epidemiological Measures. International Journal of Environmental Research and Public Health, 2016, 13, 605.	2.6	6
110	Toxoplasma gondii seroprevalence: 30-year trend in an HIV-infected US military cohort. Diagnostic Microbiology and Infectious Disease, 2016, 84, 34-35.	1.8	6
111	Noncommunicable Diseases: Yet Another Challenge for Human Immunodeficiency Virus Treatment and Care in Sub-Saharan Africa. Clinical Infectious Diseases, 2020, 71, 1874-1876.	5.8	6
112	HIV Care Continuum and Meeting 90-90-90 Targets: Cascade of Care Analyses of a U.S. Military Cohort. Military Medicine, 2020, 185, e1147-e1154.	0.8	6
113	The Intersection of HIV, Diabetes, and Race: Exploring Disparities in Diabetes Care among People Living with HIV. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822090424.	1.5	6
114	Race/ethnicity and HAART initiation in a military HIV infected cohort. AIDS Research and Therapy, 2014, 11, 10.	1.7	5
115	Delayedâ€ŧype hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy. Journal of the International AIDS Society, 2014, 17, 18799.	3.0	5
116	Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. AIDS Research and Human Retroviruses, 2015, 31, 514-518.	1.1	5
117	Parametric cost-effectiveness inference with skewed data. Computational Statistics and Data Analysis, 2016, 94, 210-220.	1.2	5
118	Extragenital chlamydia infection among active-duty women in the United States Navy. Military Medical Research, 2019, 6, 3.	3.4	5
119	Brief Report: Racial Comparison of D-Dimer Levels in US Male Military Personnel Before and After HIV Infection and Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 502-506.	2.1	4
120	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. Journal of Antimicrobial Chemotherapy, 2018, 73, 2186-2196.	3.0	4
121	Age, Race, and At-Risk Drinking in an HIV-infected U.S. Military Cohort. Military Medicine, 2019, 184, e263-e267.	0.8	4
122	Multidrug-Resistant Organisms from Ophthalmic Cultures: Antibiotic Resistance and Visual Acuity. Military Medicine, 2020, 185, e1002-e1007.	0.8	4
123	Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV. Military Medicine, 2021, 186, 279-285.	0.8	4
124	Predictive Value of an Age-Based Modification of the National Early Warning System in Hospitalized Patients With COVID-19. Open Forum Infectious Diseases, 2021, 8, ofab421.	0.9	4
125	Human papillomavirus seroprevalence among men entering military service and seroincidence after ten years of service. Msmr, 2013, 20, 21-4.	0.1	4
126	COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health. Open Forum Infectious Diseases, 2022, 9, .	0.9	4

#	Article	IF	CITATIONS
127	Azithromcyin Might Not Protect Against Treponema pallidum Infection or Reactivation in HIV Type 1-Infected Patients. Clinical Infectious Diseases, 2005, 41, 420-420.	5.8	3
128	2248. Changes in Lipid Profiles for Patients to Tenofovir Alafenamide (TAF)-Containing Regimens: Perspectives from a Military HIV-Positive Cohort. Open Forum Infectious Diseases, 2018, 5, S665-S665.	0.9	3
129	Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era. Open Forum Infectious Diseases, 2021, 8, ofab076.	0.9	3
130	Antiretroviral Therapy and Viral Suppression Among Active Duty Service Members with Incident HIV Infection — United States, January 2012–June 2018. Morbidity and Mortality Weekly Report, 2020, 69, 366-370.	15.1	3
131	Clinical factors and outcomes associated with immune non-response among virally suppressed adults with HIV from Africa and the United States. Scientific Reports, 2022, 12, 1196.	3.3	3
132	Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons. BMC Infectious Diseases, 2015, 15, 203.	2.9	2
133	Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals. Vaccine, 2017, 35, 6103-6111.	3.8	2
134	Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons. AIDS Research and Therapy, 2018, 15, 25.	1.7	2
135	Posttraumatic Stress Disorder and Neurocognitive Impairment in a U.S. Military Cohort of Persons Living with HIV. Psychiatry (New York), 2019, 82, 1-12.	0.7	2
136	Biomedical Response to Neisseria gonorrhoeae and Other Sexually Transmitted Infections in the US Military. Military Medicine, 2019, 184, 51-58.	0.8	2
137	An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection. Open Forum Infectious Diseases, 2022, 9, .	0.9	2
138	Inference for Surrogate Endpoint Validation in the Binary Case. Journal of Biopharmaceutical Statistics, 2015, 25, 1272-1284.	0.8	1
139	Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort. AIDS Research and Human Retroviruses, 2016, 32, 1187-1197.	1.1	1
140	Refractive surgery in the HIV-positive U.S. Military Natural History Study Cohort: complications and risk factors. Journal of Cataract and Refractive Surgery, 2019, 45, 1612-1618.	1.5	1
141	336. Disparities in Cardiovascular Disease Prevention Among Persons Living with HIV in the United States Military Natural History Study. Open Forum Infectious Diseases, 2019, 6, S178-S179.	0.9	1
142	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. Journal of Antimicrobial Chemotherapy, 2021, 76, 1898-1906.	3.0	1
143	Factors associated with erectile dysfunction diagnosis in men with HIV infection: a case–control study. HIV Medicine, 2021, 22, 617-622.	2.2	1
144	Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study. HIV Medicine, 2021, , .	2.2	1

#	Article	IF	CITATIONS
145	Sexual Risk Behaviors Associated with Sexually Transmitted Infections in a US Military Population Living with HIV After the Repeal of "Don't Ask, Don't Tell― AIDS Patient Care and STDs, 2020, 34, 523-533.	2.5	1
146	Reply to Tsai et al. Journal of Infectious Diseases, 2013, 208, 1186-1186.	4.0	0
147	1561The Relationship Between Self-reported Adherence and Efavirenz Blood Levels on the Appearance of HIV Viral Load Blips. Open Forum Infectious Diseases, 2014, 1, S415-S415.	0.9	0
148	1566Factors Associated with 10 Years of Continuous HIV Viral Load Suppression on HAART. Open Forum Infectious Diseases, 2014, 1, S417-S417.	0.9	0
149	Reply to Yang et al. Clinical Infectious Diseases, 2015, 60, 1444-1445.	5.8	0
150	Baseline Albumin/Globulin Ratio Predicted Progression to AIDS Among Persons with Stage 1 HIV Disease in the Pre-Combination Antiretroviral Therapy Era. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
151	Do Low Vitamin D Levels Explain Poorer Influenza Vaccine Immunogenicity Among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Adults?. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
152	Relationship of Albumin/Globulin Ratio With Biomarkers of Inflammation and Coagulation in HIV-Infected Persons Before and After Combination Antiretroviral Therapy. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
153	P3.68â€Disparity among ethnic race groups in sexual transmitted infection for lifestyle variables of male and female active duty military personnel. , 2017, , .		0
154	602. Factors Associated With Erectile Dysfunction Diagnosis in HIV-Infected Individuals: A Case–Control Study. Open Forum Infectious Diseases, 2018, 5, S220-S221.	0.9	0
155	Ophthalmic Disease Prevalence and Incidence among People Living with Human Immunodeficiency Virus in the AFRICOS Study. Ophthalmology, 2021, 128, 1104-1107.	5.2	0
156	Effects of human immunodeficiency virus status on symptom severity in influenza-like illness in an otherwise healthy adult outpatient cohort. Journal of Investigative Medicine, 2021, 69, 1230-1237.	1.6	0
157	Prospective Evaluation of an Abbreviated Test Battery to Screen for Neurocognitive Impairment in HIV-Positive Military Members. AIDS and Behavior, 2021, 25, 3347-3354.	2.7	0
158	Regimen Switching After Initial Haart By Race in a Military Cohort. Open Public Health Journal, 2017, 10, 195-207.	0.4	0
159	Anatomical Site, Viral Ribonucleic Acid Abundance, and Time of Sampling Correlate With Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 During Infection. Open Forum Infectious Diseases, 2022, 9, ofab623.	0.9	0